Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rovaleucel
- Development stage
- Phase 3
- Lead developer
- Tessa Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**Rovaleucel** is an autologous T-cell immunotherapy engineered to target Epstein-Barr virus (EBV)-positive tumor cells, utilizing EBV-specific cytotoxic T lymphocytes expanded ex vivo for adoptive cell therapy. It is under investigation primarily for EBV-associated solid tumors, including nasopharyngeal carcinoma and various advanced cancers such as nasopharyngeal, gastric, and others. Developed through collaboration between Tessa Therapeutics and the National Cancer Centre of Singapore, it has reached Phase 2 trials in multiple oncology indications as of 2023, with ongoing Phase 1 studies reported in recruiting status.
- Other names
- autologous EBV-specific T-cellsEBV-VSTs
02
Targets
Epstein-Barr virus peptide antigens presented by MHC
Beyond the preview
Go deeper on Rovaleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rovaleucel.